• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

    2/12/24 4:26:19 PM ET
    $HHLA
    Medical Specialities
    Health Care
    Get the next $HHLA alert in real time by email
    SC 13G/A 1 form_hhlacquisition_sc13ga.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G
    (Rule 13d-102)

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    HH&L Acquisition Co.
    (Name of Issuer)
     
    Class A Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)
     
    G39714103
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒  Rule 13d-1(b)
    ☐  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    CUSIP No. G39714103

    1
    NAMES OF REPORTING PERSONS
       
     Aristeia Capital, L.L.C.
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     Delaware
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
       
     0 (1)
       
       
    6
    SHARED VOTING POWER
       
     0
       
       
    7
    SOLE DISPOSITIVE POWER
       
     0 (1)
       
       
    8
    SHARED DISPOSITIVE POWER
       
     0
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     0 (1)
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     0.00 %
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     IA, OO
       
       

    (1)
    Aristeia Capital, L.L.C. is the investment manager of, and has voting and investment control with respect to the securities described herein held by, one or more private investment funds.




    Item 1(a).
    Name of Issuer:
    HH&L Acquisition Co. (the “Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    Suite 2001-2002, 20/F, York House
    The Landmark, 15 Queen's Road Central, Central, Hong Kong
    Item 2(a).
    Name of Person Filing:
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:
    Item 2(c).
    Citizenship:
    Aristeia Capital, L.L.C.
    One Greenwich Plaza, Suite 300
    Greenwich, CT 06830
    Delaware limited liability company
    Item 2(d).
    Title of Class of Securities:
    Class A Ordinary Shares, par value $0.0001 per share (“Shares”)
    Item 2(e).
    CUSIP Number:
    G39714103
    Item 3.   
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a)
    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e)
    ☒ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f)
    ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g)
    ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h)
    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i)
    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j)
    ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k)
    ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .

    Item 4.   
    Ownership.
    The following is information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 as of 12/31/2023.

    Items 5-9 and 11 of the cover page to this Schedule 13G are incorporated herein by reference.

    (a) Amount beneficially owned:  0

    (b) Percent of class:  0.00 %

    (c) Number of shares as to which the person has:


    (i)
    Sole power to vote or to direct the vote:  0


    (ii)
    Shared power to vote or to direct the vote:  0


    Item 5.   
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6.   
    Ownership of More Than Five Percent on Behalf of Another Person.
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

    N/A

    Item 7.   
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

    N/A

    Item 8.   
    Identification and Classification of Members of the Group.
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

    N/A

    Item 9.   
    Notice of Dissolution of Group.
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

    N/A

    Item 10.   
    Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2024

     
    ARISTEIA CAPITAL, L.L.C.
       
     
    By:
     /s/  Andrew B. David
       
    ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
       
    Name:   Andrew B. David
       
    Title:     Chief Operating Officer







    Get the next $HHLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HHLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HHLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

      PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta's leadership and commitment to excellence. "This CAP Accreditation is a tremendous accomplishment that signifies DiaCarta's commitment to excellence and I am proud of our team's dedication in support this major milestone," said Zheng 

      5/9/23 5:51:25 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

      Abstracts demonstrating XNA technology's improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technology's potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to

      4/16/23 2:00:00 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

      PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection. The test is designed for use by authorized laboratories on the most popular qPCR instruments, including the Thermo Fisher (ABI) QuantStudio5, Thermo Fisher (ABI) 7500 Fast Dx, Bio-Rad CFX384, and Roche LightCycler 480 II Systems. QuantiVirusTM MPXV test targets two di

      1/12/23 8:30:00 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by HH&L Acquisition Co.

      25-NSE - HH&L Acquisition Co. (0001824185) (Subject)

      2/23/24 10:50:57 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • HH&L Acquisition Co. filed SEC Form 8-K: Other Events

      8-K - HH&L Acquisition Co. (0001824185) (Filer)

      2/7/24 11:57:39 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by HH&L Acquisition Co.

      PRE 14A - HH&L Acquisition Co. (0001824185) (Filer)

      1/23/24 5:14:45 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highbridge Capital Management Llc sold $2,687,500 worth of Class A Ordinary Shares (250,000 units at $10.75) (SEC Form 4)

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      1/12/24 4:15:16 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 500,000 units of Class A Ordinary Shares

      3 - HH&L Acquisition Co. (0001824185) (Issuer)

      8/15/23 4:30:21 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 4 filed by HH&L Investment Co.

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      5/19/21 11:16:35 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/14/24 5:09:41 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/13/24 8:00:58 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

      SC 13G/A - HH&L Acquisition Co. (0001824185) (Subject)

      2/12/24 4:26:19 PM ET
      $HHLA
      Medical Specialities
      Health Care